文献速递临床试验与 GCP流行病学与生物统计

妊娠期双氢青蒿素哌喹间歇性预防治疗与幼儿期疟疾风险的随机对照试验

Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial.
PubMed 文献 · PLoS Med · 2018-07-17

在乌干达托罗罗开展的双盲随机对照试验,比较妊娠期间歇性预防治疗使用双氢青蒿素哌喹(DP)与磺胺多辛-乙胺嘧啶(SP)后,子代婴儿期疟疾发病率。婴儿出生后均接受DP每12周化学预防。与SP8w组相比,DP4w组子代疟疾发病率更高(aIRR 1.92,95%CI 1.00-3.65,p=0.049),且该关联受婴儿性别修饰,女性子代风险显著增加(aIRR 4.39,95%CI 1.87-10.3,p=0.001)。

要点

  • 妊娠期IPTp-DP未降低子代婴儿期疟疾风险,DP4w组反而更高。
  • 女性子代中,母亲接受DP4w者疟疾发病率显著高于SP8w者。
  • 男性子代中未观察到IPTP方案与疟疾风险的显著关联。

核心结论

  • 在婴儿期接受DP化学预防的背景下,妊娠期使用IPTp-DP并未降低儿童期疟疾发病率,反而可能与女性子代疟疾发病率增加相关。

研究设计与样本

  • 双盲随机对照试验,在乌干达托罗罗开展,比较母亲接受IPTp-SP每8周(n=100)、IPTp-DP每8周(n=44)或IPTp-DP每4周(n=47)的子代疟疾指标。
  • 婴儿出生后8周至2岁期间每12周接受一次DP化学预防。
  • 主要结局为出生后前2年疟疾发病率,分析时调整双胎聚类及母亲年龄、孕次和入组时疟原虫血症状态。

主要发现

  • 与SP8w组(0.24例/人年)相比,DP4w组子代疟疾发病率更高(0.42例/人年,aIRR 1.92;95%CI 1.00-3.65,p=0.049),DP8w组无显著差异(0.30例/人年,aIRR 1.44;95%CI 0.68-3.05,p=0.34)。
  • 女性子代中,DP4w组较SP8w组疟疾发病率显著升高(0.65 vs 0.20例/人年,aIRR 4.39,95%CI 1.87-10.3,p=0.001);男性子代中无显著关联(0.20 vs 0.28例/人年,aIRR 0.66,95%CI 0.25-1.75,p=0.42)。
  • 探索性分析中,脐带血疟疾特异性抗体水平在各IPTp组和性别间相似;女性子代中,DP4w组婴儿期平均哌喹(PQ)水平低于SP8w组(coef 0.81,95%CI 0.65-1.00,p=0.048)及男性DP4w组(coef 0.72,95%CI 0.57-0.91,p=0.006)。

临床怎么用

  • 妊娠期IPTp-DP方案选择需考虑对子代疟疾风险的潜在影响,尤其是女性子代。
  • 婴儿期化学预防方案应结合母亲妊娠期IPTp用药史进行个体化评估。

局限性

  • 样本量较小。
  • 婴儿期每12周提供DP化学预防可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intermittent preventive treatment of malaria in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) has been shown to reduce the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (IPTp-SP). However, limited data exist on how IPTp regimens impact malaria risk during infancy. We conducted a double-blinded randomized controlled trial (RCT) to test the hypothesis that children born to mothers given IPTp-DP would have a lower incidence of malaria during infancy compared to children born to mothers who received IPTp-SP. METHODS AND FINDINGS: We compared malaria metrics among children in Tororo, Uganda, born to women randomized to IPTp-SP given every 8 weeks (SP8w, n = 100), IPTp-DP every 8 weeks (DP8w, n = 44), or IPTp-DP every 4 weeks (DP4w, n = 47). After birth, children were given chemoprevention with DP every 12 weeks from 8 weeks to 2 years of age. The primary outcome was incidence of malaria during the first 2 years of life. Secondary outcomes included time to malaria from birth and time to parasitemia following each dose of DP given during infancy. Results are reported after adjustment for clustering (twin gestation) and potential confounders (maternal age, gravidity, and maternal parasitemia status at enrolment).The study took place between June 2014 and May 2017. Compared to children whose mothers were randomized to IPTp-SP8w (0.24 episodes per person year [PPY]), the incidence of malaria was higher in children born to mothers who received IPTp-DP4w (0.42 episodes PPY, adjusted incidence rate ratio [aIRR] 1.92; 95% CI 1.00-3.65, p = 0.049) and nonsignificantly higher in children born to mothers who received IPT-DP8w (0.30 episodes PPY, aIRR 1.44; 95% CI 0.68-3.05, p = 0.34). However, these associations were modified by infant sex. Female children whose mothers were randomized to IPTp-DP4w had an apparently 4-fold higher incidence of malaria compared to female children whose mothers were randomized to IPTp-SP8w (0.65 versus 0.20 episodes PPY, aIRR 4.39, 95% CI 1.87-10.3, p = 0.001), but no significant association was observed in male children (0.20 versus 0.28 episodes PPY, aIRR 0.66, 95% CI 0.25-1.75, p = 0.42). Nonsignificant increases in malaria incidence were observed among female, but not male, children born to mothers who received DP8w versus SP8w. In exploratory analyses, levels of malaria-specific antibodies in cord blood were similar between IPTp groups and sex. However, female children whose mothers were randomized to IPTp-DP4w had lower mean piperaquine (PQ) levels during infancy compared to female children whose mothers received IPTp-SP8w (coef 0.81, 95% CI 0.65-1.00, p = 0.048) and male children whose mothers received IPTp-DP4w (coef 0.72, 95% CI 0.57-0.91, p = 0.006). There were no significant sex-specific differences in PQ levels among children whose mothers were randomized to IPTp-SP8w or IPTp-DP8w. The main limitations were small sample size and childhood provision of DP every 12 weeks in infancy. CONCLUSIONS: Contrary to our hypothesis, preventing malaria in pregnancy with IPTp-DP in the context of chemoprevention with DP during infancy does not lead to a reduced incidence of malaria in childhood; in this setting, it may be associated with an increased incidence of malaria in females. Future studies are needed to better understand the biological mechanisms of in utero drug exposure on drug metabolism and how this may affect the dosing of antimalarial drugs for treatment and prevention during infancy. TRIAL REGISTRATION: ClinicalTrials.gov number NCT02163447.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Jagannathan P, Kakuru A, Okiring J, et al. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med. 2018. PMID: 30016328. doi:10.1371/journal.pmed.1002606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。